Asia

Juno, WuXi launch JW Biotechnology in China

Monday, April 11, 2016

Juno Therapeutics, a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, and WuXi AppTec, an open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, have started a new company in China. JW Biotechnology (Shanghai) Co., Ltd‘s mission is to build China’s  cell therapy company by leveraging Juno’s world-class chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies together with WuXi AppTec’s R&D and manufacturing platform and local expertise to develop novel cell-based immunotherapies for patients with hematologic and solidorgan cancers. 

[Read More]

Quintiles honored as Best CRO in Asia

Thursday, March 31, 2016

Quintiles has been named the Best CRO in Asia at the 2016 BioPharma Asia Industry Awards, winning the honor for the fourth time in the event’s six-year history. The award goes to the CRO that best demonstrates an ongoing commitment to improving clinical research services in Asia and reducing lead times for customers.

[Read More]

BioPharmaSpec expands into Asia

Thursday, March 24, 2016

BioPharmaSpec, a CRO providing a full range of characterization services for the biotechnology industry, is expanding its business in Asia with business development teams in India and the Asia Pacific region. This will allow scientists in the region to access BioPharmaSpec’s cost-effective, efficient characterization strategies and help accelerate the development of their biosimilars.

[Read More]

The changing landscape of clinical trials in Asia and the Pacific Rim

Tuesday, December 1, 2015

In recent years, the clinical trial landscape in Asia and the Pacific Rim has evolved faster than in most other regions. More than half of the world’s population lives in this rapidly developing area, which includes advanced economies such as Australia, Singapore and South Korea, as well as countries with vast populations like India and China.

[Read More]

Parexel, Kyoto ink agreement for Japan’s biopharmaceutical workforce

Friday, November 13, 2015

Parexel International, a global biopharmaceutical services provider, and Kyoto Pharmaceutical University (KPU), a private pharmacy and science university, have announced a new joint program for clinical research and clinical trial management. The academic program offers undergraduate students an accredited, seven-week course designed to prepare them for careers in the biopharmaceutical industry.

[Read More]

Hepalink to acquire Cytovance

Wednesday, August 26, 2015

Hepalink USA, a China-based global supplier of heparin sodium API, has entered into a definitive agreement to acquire Cytovance Biologics, a biopharmaceutical contract development manufacturing (CDMO) company, for $205.68 million in cash plus certain contingent payments.

[Read More]

China to reform drug approval system

Thursday, August 20, 2015

China has decided to reform its appraisal and approval system for drugs and medical instruments with the aim of improving drug safety and quality and encouraging innovation.

[Read More]